Literature DB >> 29907693

Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs.

Julie M Diamond1,2, Claire Vanpouille-Box2, Sheila Spada2, Nils-Petter Rudqvist2, Jessica R Chapman3, Beatrix M Ueberheide3,4, Karsten A Pilones2, Yasmeen Sarfraz2, Silvia C Formenti2, Sandra Demaria5,6.   

Abstract

Radiotherapy (RT) used at immunogenic doses leads to accumulation of cytosolic double-stranded DNA (dsDNA) in cancer cells, which activates type I IFN (IFN-I) via the cGAS/STING pathway. Cancer cell-derived IFN-I is required to recruit BATF3-dependent dendritic cells (DC) to poorly immunogenic tumors and trigger antitumor T-cell responses in combination with immune checkpoint blockade. We have previously demonstrated that the exonuclease TREX1 regulates radiation immunogenicity by degrading cytosolic dsDNA. Tumor-derived DNA can also activate cGAS/STING-mediated production of IFN-I by DCs infiltrating immunogenic tumors. However, how DNA from cancer cells is transferred to the cytoplasm of DCs remains unclear. Here, we showed that tumor-derived exosomes (TEX) produced by irradiated mouse breast cancer cells (RT-TEX) transfer dsDNA to DCs and stimulate DC upregulation of costimulatory molecules and STING-dependent activation of IFN-I. In vivo, RT-TEX elicited tumor-specific CD8+ T-cell responses and protected mice from tumor development significantly better than TEX from untreated cancer cells in a prophylactic vaccination experiment. We demonstrated that the IFN-stimulatory dsDNA cargo of RT-TEX is regulated by TREX1 expression in the parent cells. Overall, these results identify RT-TEX as a mechanism whereby IFN-stimulatory dsDNA is transferred from irradiated cancer cells to DCs. We have previously shown that the expression of TREX1 is dependent on the RT dose size. Thus, these data have important implications for the use of RT with immunotherapy. Cancer Immunol Res; 6(8); 910-20. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29907693      PMCID: PMC6072562          DOI: 10.1158/2326-6066.CIR-17-0581

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  45 in total

Review 1.  Radiotherapy and immunogenic cell death.

Authors:  Encouse B Golden; Lionel Apetoh
Journal:  Semin Radiat Oncol       Date:  2015-01       Impact factor: 5.934

Review 2.  Immunogenic cell death in cancer and infectious disease.

Authors:  Lorenzo Galluzzi; Aitziber Buqué; Oliver Kepp; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2016-10-17       Impact factor: 53.106

3.  Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming.

Authors:  J Wolfers; A Lozier; G Raposo; A Regnault; C Théry; C Masurier; C Flament; S Pouzieux; F Faure; T Tursz; E Angevin; S Amigorena; L Zitvogel
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

4.  Establishment and characterization of BALB/c lymphoma lines with B cell properties.

Authors:  K J Kim; C Kanellopoulos-Langevin; R M Merwin; D H Sachs; R Asofsky
Journal:  J Immunol       Date:  1979-02       Impact factor: 5.422

5.  Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells.

Authors:  Robert Gastpar; Mathias Gehrmann; Maria A Bausero; Alexzander Asea; Catharina Gross; Josef A Schroeder; Gabriele Multhoff
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

Review 6.  Exosomes as intercellular signalosomes and pharmacological effectors.

Authors:  Michel Record; Caroline Subra; Sandrine Silvente-Poirot; Marc Poirot
Journal:  Biochem Pharmacol       Date:  2011-03-01       Impact factor: 5.858

Review 7.  Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors:  Padmanee Sharma; James P Allison
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

8.  Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.

Authors:  Héctor Peinado; Maša Alečković; Simon Lavotshkin; Irina Matei; Bruno Costa-Silva; Gema Moreno-Bueno; Marta Hergueta-Redondo; Caitlin Williams; Guillermo García-Santos; Cyrus Ghajar; Ayuko Nitadori-Hoshino; Caitlin Hoffman; Karen Badal; Benjamin A Garcia; Margaret K Callahan; Jianda Yuan; Vilma R Martins; Johan Skog; Rosandra N Kaplan; Mary S Brady; Jedd D Wolchok; Paul B Chapman; Yibin Kang; Jacqueline Bromberg; David Lyden
Journal:  Nat Med       Date:  2012-06       Impact factor: 53.440

9.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

10.  Exosomes communicate protective messages during oxidative stress; possible role of exosomal shuttle RNA.

Authors:  Maria Eldh; Karin Ekström; Hadi Valadi; Margareta Sjöstrand; Bob Olsson; Margareta Jernås; Jan Lötvall
Journal:  PLoS One       Date:  2010-12-17       Impact factor: 3.240

View more
  93 in total

Review 1.  Tumor-derived extracellular vesicles: molecular parcels that enable regulation of the immune response in cancer.

Authors:  Colin Sheehan; Crislyn D'Souza-Schorey
Journal:  J Cell Sci       Date:  2019-10-15       Impact factor: 5.285

Review 2.  The abscopal effect 67 years later: from a side story to center stage.

Authors:  Sandra Demaria; Silvia C Formenti
Journal:  Br J Radiol       Date:  2020-02-28       Impact factor: 3.039

3.  Exosome-Containing Preparations From Postirradiated Mouse Melanoma Cells Delay Melanoma Growth In Vivo by a Natural Killer Cell-Dependent Mechanism.

Authors:  Kishore Kumar Jella; Tahseen H Nasti; Zhentian Li; David H Lawson; Jeffrey M Switchenko; Rafi Ahmed; William S Dynan; Mohammad K Khan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-06-17       Impact factor: 7.038

Review 4.  STING pathway agonism as a cancer therapeutic.

Authors:  Blake A Flood; Emily F Higgs; Shuyin Li; Jason J Luke; Thomas F Gajewski
Journal:  Immunol Rev       Date:  2019-07       Impact factor: 12.988

5.  TREX1 - Apex predator of cytosolic DNA metabolism.

Authors:  Sean R Simpson; Wayne O Hemphill; Teesha Hudson; Fred W Perrino
Journal:  DNA Repair (Amst)       Date:  2020-06-12

Review 6.  The Promise of Combining Radiation Therapy With Immunotherapy.

Authors:  Justin C Jagodinsky; Paul M Harari; Zachary S Morris
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-04-23       Impact factor: 7.038

Review 7.  Tumor-derived extracellular vesicles: insights into bystander effects of exosomes after irradiation.

Authors:  Nasrollah Jabbari; Mohammad Karimipour; Majid Khaksar; Elinaz Akbariazar; Morteza Heidarzadeh; Behnam Mojarad; Hossein Aftab; Reza Rahbarghazi; Jafar Rezaie
Journal:  Lasers Med Sci       Date:  2019-09-16       Impact factor: 3.161

Review 8.  Immunological impact of cell death signaling driven by radiation on the tumor microenvironment.

Authors:  Maria Esperanza Rodriguez-Ruiz; Ilio Vitale; Kevin J Harrington; Ignacio Melero; Lorenzo Galluzzi
Journal:  Nat Immunol       Date:  2019-12-23       Impact factor: 25.606

Review 9.  Inflammatory microenvironment remodelling by tumour cells after radiotherapy.

Authors:  Martin McLaughlin; Emmanuel C Patin; Malin Pedersen; Anna Wilkins; Magnus T Dillon; Alan A Melcher; Kevin J Harrington
Journal:  Nat Rev Cancer       Date:  2020-03-11       Impact factor: 60.716

Review 10.  Exosomes in Breast Cancer - Mechanisms of Action and Clinical Potential.

Authors:  Tiantong Liu; Jagmohan Hooda; Jennifer M Atkinson; Theresa L Whiteside; Steffi Oesterreich; Adrian V Lee
Journal:  Mol Cancer Res       Date:  2021-02-24       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.